In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
Trevi Therapeutics Inc (NASDAQ: TRVI) closed the day trading at $5.47 down -2.67% from the previous closing price of $5.62. In other words, the price has decreased by -$2.67 from its previous closing price. On the day, 1.5 million shares were traded. TRVI stock price reached its highest trading level at $5.655 during the session, while it also had its lowest trading level at $5.41.
Ratios:
For a better understanding of TRVI, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.38 and its Current Ratio is at 15.38. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on May 28, 2025, initiated with a Buy rating and assigned the stock a target price of $21.
On March 10, 2025, Raymond James Upgraded its rating to Strong Buy which previously was Outperform and also upped its target price recommendation from $9 to $29.
Needham reiterated its Buy rating for the stock on March 10, 2025, while the target price for the stock was revised from $8 to $25.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 25 ’25 when SCIASCIA THOMAS sold 2,631 shares for $6.60 per share. The transaction valued at 17,365 led to the insider holds 221,373 shares of the business.
GOOD JENNIFER L sold 5,263 shares of TRVI for $34,625 on Mar 21 ’25. The President & CEO now owns 213,313 shares after completing the transaction at $6.58 per share. On Mar 21 ’25, another insider, GOOD JENNIFER L, who serves as the Officer of the company, bought 5,263 shares for $6.58 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TRVI now has a Market Capitalization of 665999808 and an Enterprise Value of 454243872.
Stock Price History:
The Beta on a monthly basis for TRVI is 0.48, which has changed by 1.0410447 over the last 52 weeks, in comparison to a change of 0.12632763 over the same period for the S&P500. Over the past 52 weeks, TRVI has reached a high of $7.48, while it has fallen to a 52-week low of $2.36. The 50-Day Moving Average of the stock is -13.34%, while the 200-Day Moving Average is calculated to be 18.49%.
Shares Statistics:
Over the past 3-months, TRVI traded about 1.75M shares per day on average, while over the past 10 days, TRVI traded about 1538790 shares per day. A total of 99.89M shares are outstanding, with a floating share count of 69.87M. Insiders hold about 41.36% of the company’s shares, while institutions hold 43.98% stake in the company. Shares short for TRVI as of 1749772800 were 7627036 with a Short Ratio of 4.36, compared to 1747267200 on 6869392. Therefore, it implies a Short% of Shares Outstanding of 7627036 and a Short% of Float of 7.26.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
